Urologia

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dr. Nuno Vau	Recrutamento	2014-002009-40

Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	NCT Number
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Prof. Doutor Carlo Greco	Recrutamento	NCT02570919

A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar e Universitário de Coimbra Praceto Prof. Mota Pinto 3000-075 Coimbra - Portugal	Prof. Dr. Arnaldo Figueiredo	Recrutamento	2016-002778-11
Fundação Champalimaud Av. Basília 1400-038 Lisboa - Portugal	Dr. Nuno Vau	Recrutamento	2016-002778-11
Hospital de Santa Maria Av. Prof. Egas Moniz 1649-035 Lisboa - Portugal	Prof. Dr. Luís Costa	Recrutamento	2016-002778-11
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Maria Joaquina Maurício	Recrutamento	2016-002778-11

A randomized, open label, multi-center, Phase II/III study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Joana Febra	Recrutamento	2016-004340-11

CA209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital Beatriz Ângelo Av. Carlos Teixeira, 514 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-003336-37
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Maragrida Brito	Recrutamento	2017-003336-37

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Jorge Oliveira	Recrutamento	2018-001967-22

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Filipa Carneiro	Recrutamento	2017-003344-21